Preload Image
Preload Image
Report Store mobile icon
Global Human Papillomavirus (HPV) Vaccines Market Growth 2024-2030

Global Human Papillomavirus (HPV) Vaccines Market Growth 2024-2030

2024

Global Human Papillomavirus (HPV) Vaccines Market Growth 2024-2030

The global Human Papillomavirus (HPV) Vaccines market was valued at US$ 17.28 billion in 2024, reflecting increasing demand for cancer prevention and immunization.

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global Human Papillomavirus (HPV) vaccines market is experiencing significant growth due to the increasing awareness about HPV-related diseases and the effectiveness of vaccines in preventing these conditions. HPV is a major cause of cervical cancer, as well as other cancers, including those of the anus, vulva, vagina, penis, and oropharynx. It is one of the most common sexually transmitted infections, with over 100 types, many of which do not cause immediate symptoms but can lead to serious health complications over time. The primary motivation behind the use of HPV vaccines is to prevent the types of HPV that cause the majority of cervical cancers and other related diseases. The World Health Organization (WHO) and national health authorities have emphasized the importance of vaccinating both females and males to reduce the incidence of these cancers. The development of HPV vaccines, such as Gardasil and Cervarix, has revolutionized the approach to cancer prevention, making it possible to reduce the burden of these diseases. These vaccines target the most high-risk strains of HPV, particularly HPV types 16 and 18, which are responsible for around 70% of cervical cancer cases globally. As the benefits of vaccination in reducing cancer risks become more widely recognized, there is a growing push for widespread vaccination programs, particularly in low- and middle-income countries, where the incidence of cervical cancer is higher due to limited access to screening and treatment. In addition to cervical cancer, HPV vaccines are also being utilized for the prevention of other HPV-related cancers and conditions, including genital warts, which affect both men and women, and are associated with a significant healthcare burden. The market is further supported by government initiatives, partnerships with international health organizations, and funding aimed at promoting vaccination programs to reduce the prevalence of HPV-related diseases. The ongoing research and development efforts are also contributing to the growth of the market, with new vaccines and formulations being developed to offer broader protection against more HPV strains.

According to Publisher, the global Human Papillomavirus (HPV) Vaccines market size was valued at US$ 17280 million in 2024. With growing demand in downstream market, the Human Papillomavirus (HPV) Vaccines is forecast to a readjusted size of US$ 26190 million by 2030 with a CAGR of 6.1% during review period. The HPV vaccines market is segmented by vaccine type, with quadrivalent vaccines, bivalent vaccines, and nonavalent vaccines being the primary categories. Quadrivalent vaccines, such as Gardasil, offer protection against four strains of HPV, including types 6, 11, 16, and 18. These vaccines have been widely used and have proven to be effective in preventing HPV infections and related diseases, including cervical cancer and genital warts. Bivalent vaccines, like Cervarix, focus on providing protection against the two most high-risk strains, HPV types 16 and 18, which are responsible for the majority of cervical cancers. While they offer a more targeted approach, the quadrivalent vaccines have gained more widespread adoption due to their broader coverage, particularly in preventing both cancerous lesions and genital warts. In recent years, the nonavalent vaccines, such as Gardasil 9, have gained popularity, as they provide protection against nine different HPV strains, expanding the range of protection against additional high-risk and low-risk HPV types. The nonavalent vaccines offer the potential for greater long-term protection against a broader range of HPV-related diseases. These vaccines are considered a significant advancement in HPV vaccination, as they increase the potential for preventing more types of HPV infections and the cancers they cause. The growing preference for nonavalent vaccines is driving the market towards more comprehensive vaccination options, as they offer more extensive coverage and are better suited for global vaccination programs. The increasing availability of these vaccines, along with their higher efficacy rates and broader protection, is expected to drive further adoption of HPV vaccines worldwide, contributing to the overall growth of the market.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The HPV vaccines market is also segmented by application, with the primary target groups being young girls, young boys, and adults. The vaccination of young girls, particularly between the ages of 9 and 14, is a key focus in many countries, as this age group is considered ideal for vaccination before the onset of sexual activity, when exposure to HPV becomes more likely. Vaccinating girls at a young age ensures that they are protected before they are exposed to the virus, thereby preventing infections that could lead to cervical cancer and other HPV-related diseases later in life. In many countries, school-based vaccination programs are implemented to provide easy access to the vaccine for adolescent girls, often as part of routine immunization schedules. The vaccination of boys is also gaining traction, as research has shown that vaccinating boys can help reduce the transmission of HPV to females and prevent HPV-related cancers that affect men, such as penile and anal cancers. In some countries, HPV vaccination for boys is recommended to ensure herd immunity and to prevent the spread of the virus within the population. Additionally, HPV vaccines are being increasingly administered to adults, particularly those who were not vaccinated during childhood or those who may be at higher risk for HPV infections due to certain behaviors or health conditions. Adult vaccination programs are also critical in ensuring broader population protection, especially in countries where the incidence of HPV-related cancers remains high due to gaps in vaccination coverage. This segment is expected to witness significant growth as healthcare professionals and policymakers increasingly recognize the importance of vaccinating both genders across all age groups to reduce the global burden of HPV-related diseases. The growing emphasis on vaccination in both developed and developing countries is expected to drive the demand for HPV vaccines in the coming years, expanding the market across diverse populations and contributing to public health goals.

Geographically, the HPV vaccines market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa, with North America holding the largest market share. The availability of advanced healthcare infrastructure, high levels of awareness about HPV vaccination, and well-established immunization programs in countries like the United States and Canada contribute to the dominance of this region. In North America, HPV vaccination is widely recommended for both girls and boys, and the vaccination rate remains high, supported by governmental health policies and private healthcare providers. Europe follows closely behind, with many countries, such as the United Kingdom, Germany, and France, having strong HPV vaccination programs in place. The European market is benefiting from government-funded initiatives aimed at increasing vaccination coverage and reducing the incidence of HPV-related cancers. The Asia-Pacific region is expected to experience the highest growth rate in the HPV vaccines market due to the increasing awareness of HPV infections and related diseases, as well as the growing adoption of vaccination programs in countries like China, India, and Japan. These countries have large populations and face significant healthcare challenges, making widespread vaccination efforts crucial in preventing the long-term burden of HPV-related cancers. Latin America and the Middle East and Africa are also seeing growing adoption of HPV vaccines, driven by improving healthcare access, educational campaigns, and international health organization support. While these regions are currently witnessing slower adoption rates compared to developed regions, efforts to increase HPV vaccination rates are expected to drive market growth over the next few years. The global HPV vaccines market is expected to continue expanding as new vaccines and innovative vaccination strategies are introduced, aiming to reduce the incidence of HPV-related cancers worldwide and protect future generations from the harmful effects of the virus.


Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Human Papillomavirus (HPV) Vaccines Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Country/Region, 2019, 2023 & 2030
  • 2.2 Human Papillomavirus (HPV) Vaccines Segment by Type
  • 2.2.1 2-Valent Vaccine
  • 2.2.2 4-Valent Vaccine
  • 2.3 Human Papillomavirus (HPV) Vaccines Sales by Type
  • 2.3.1 Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Human Papillomavirus (HPV) Vaccines Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Human Papillomavirus (HPV) Vaccines Sale Price by Type (2019-2024)
  • 2.4 Human Papillomavirus (HPV) Vaccines Segment by Application
  • 2.4.1 Research & Academic Laboratories
  • 2.4.2 Pharmaceutical & Biotechnology Companies
  • 2.4.3 Others
  • 2.5 Human Papillomavirus (HPV) Vaccines Sales by Application
  • 2.5.1 Global Human Papillomavirus (HPV) Vaccines Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Human Papillomavirus (HPV) Vaccines Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Human Papillomavirus (HPV) Vaccines Sale Price by Application (2019-2024)
  • 3 Global Human Papillomavirus (HPV) Vaccines by Company
  • 3.1 Global Human Papillomavirus (HPV) Vaccines Breakdown Data by Company
  • 3.1.1 Global Human Papillomavirus (HPV) Vaccines Annual Sales by Company (2019-2024)
  • 3.1.2 Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Company (2019-2024)
  • 3.2 Global Human Papillomavirus (HPV) Vaccines Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Human Papillomavirus (HPV) Vaccines Revenue by Company (2019-2024)
  • 3.2.2 Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Company (2019-2024)
  • 3.3 Global Human Papillomavirus (HPV) Vaccines Sale Price by Company
  • 3.4 Key Manufacturers Human Papillomavirus (HPV) Vaccines Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Human Papillomavirus (HPV) Vaccines Product Location Distribution
  • 3.4.2 Players Human Papillomavirus (HPV) Vaccines Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Human Papillomavirus (HPV) Vaccines by Geographic Region
  • 4.1 World Historic Human Papillomavirus (HPV) Vaccines Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Human Papillomavirus (HPV) Vaccines Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Human Papillomavirus (HPV) Vaccines Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Human Papillomavirus (HPV) Vaccines Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Human Papillomavirus (HPV) Vaccines Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Human Papillomavirus (HPV) Vaccines Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Human Papillomavirus (HPV) Vaccines Sales Growth
  • 4.4 APAC Human Papillomavirus (HPV) Vaccines Sales Growth
  • 4.5 Europe Human Papillomavirus (HPV) Vaccines Sales Growth
  • 4.6 Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales Growth
  • 5 Americas
  • 5.1 Americas Human Papillomavirus (HPV) Vaccines Sales by Country
  • 5.1.1 Americas Human Papillomavirus (HPV) Vaccines Sales by Country (2019-2024)
  • 5.1.2 Americas Human Papillomavirus (HPV) Vaccines Revenue by Country (2019-2024)
  • 5.2 Americas Human Papillomavirus (HPV) Vaccines Sales by Type
  • 5.3 Americas Human Papillomavirus (HPV) Vaccines Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Human Papillomavirus (HPV) Vaccines Sales by Region
  • 6.1.1 APAC Human Papillomavirus (HPV) Vaccines Sales by Region (2019-2024)
  • 6.1.2 APAC Human Papillomavirus (HPV) Vaccines Revenue by Region (2019-2024)
  • 6.2 APAC Human Papillomavirus (HPV) Vaccines Sales by Type
  • 6.3 APAC Human Papillomavirus (HPV) Vaccines Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Human Papillomavirus (HPV) Vaccines by Country
  • 7.1.1 Europe Human Papillomavirus (HPV) Vaccines Sales by Country (2019-2024)
  • 7.1.2 Europe Human Papillomavirus (HPV) Vaccines Revenue by Country (2019-2024)
  • 7.2 Europe Human Papillomavirus (HPV) Vaccines Sales by Type
  • 7.3 Europe Human Papillomavirus (HPV) Vaccines Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Human Papillomavirus (HPV) Vaccines by Country
  • 8.1.1 Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Human Papillomavirus (HPV) Vaccines Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales by Type
  • 8.3 Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Human Papillomavirus (HPV) Vaccines
  • 10.3 Manufacturing Process Analysis of Human Papillomavirus (HPV) Vaccines
  • 10.4 Industry Chain Structure of Human Papillomavirus (HPV) Vaccines
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Human Papillomavirus (HPV) Vaccines Distributors
  • 11.3 Human Papillomavirus (HPV) Vaccines Customer
  • 12 World Forecast Review for Human Papillomavirus (HPV) Vaccines by Geographic Region
  • 12.1 Global Human Papillomavirus (HPV) Vaccines Market Size Forecast by Region
  • 12.1.1 Global Human Papillomavirus (HPV) Vaccines Forecast by Region (2025-2030)
  • 12.1.2 Global Human Papillomavirus (HPV) Vaccines Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Human Papillomavirus (HPV) Vaccines Forecast by Type
  • 12.7 Global Human Papillomavirus (HPV) Vaccines Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Merck
  • 13.1.1 Merck Company Information
  • 13.1.2 Merck Human Papillomavirus (HPV) Vaccines Product Portfolios and Specifications
  • 13.1.3 Merck Human Papillomavirus (HPV) Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Merck Main Business Overview
  • 13.1.5 Merck Latest Developments
  • 13.2 GSK
  • 13.2.1 GSK Company Information
  • 13.2.2 GSK Human Papillomavirus (HPV) Vaccines Product Portfolios and Specifications
  • 13.2.3 GSK Human Papillomavirus (HPV) Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 GSK Main Business Overview
  • 13.2.5 GSK Latest Developments
  • 13.3 Walvax
  • 13.3.1 Walvax Company Information
  • 13.3.2 Walvax Human Papillomavirus (HPV) Vaccines Product Portfolios and Specifications
  • 13.3.3 Walvax Human Papillomavirus (HPV) Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 Walvax Main Business Overview
  • 13.3.5 Walvax Latest Developments
  • 14 Research Findings and Conclusion


Table 1. Human Papillomavirus (HPV) Vaccines Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Human Papillomavirus (HPV) Vaccines Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of 2-Valent Vaccine
Table 4. Major Players of 4-Valent Vaccine
Table 5. Global Human Papillomavirus (HPV) Vaccines Sales by Type (2019-2024) & (K Units)
Table 6. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Type (2019-2024)
Table 7. Global Human Papillomavirus (HPV) Vaccines Revenue by Type (2019-2024) & ($ million)
Table 8. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Type (2019-2024)
Table 9. Global Human Papillomavirus (HPV) Vaccines Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Human Papillomavirus (HPV) Vaccines Sales by Application (2019-2024) & (K Units)
Table 11. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Application (2019-2024)
Table 12. Global Human Papillomavirus (HPV) Vaccines Revenue by Application (2019-2024)
Table 13. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Application (2019-2024)
Table 14. Global Human Papillomavirus (HPV) Vaccines Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Human Papillomavirus (HPV) Vaccines Sales by Company (2019-2024) & (K Units)
Table 16. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Company (2019-2024)
Table 17. Global Human Papillomavirus (HPV) Vaccines Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Company (2019-2024)
Table 19. Global Human Papillomavirus (HPV) Vaccines Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Human Papillomavirus (HPV) Vaccines Producing Area Distribution and Sales Area
Table 21. Players Human Papillomavirus (HPV) Vaccines Products Offered
Table 22. Human Papillomavirus (HPV) Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Human Papillomavirus (HPV) Vaccines Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Human Papillomavirus (HPV) Vaccines Sales Market Share Geographic Region (2019-2024)
Table 27. Global Human Papillomavirus (HPV) Vaccines Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Human Papillomavirus (HPV) Vaccines Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Country/Region (2019-2024)
Table 31. Global Human Papillomavirus (HPV) Vaccines Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Human Papillomavirus (HPV) Vaccines Sales by Country (2019-2024) & (K Units)
Table 34. Americas Human Papillomavirus (HPV) Vaccines Sales Market Share by Country (2019-2024)
Table 35. Americas Human Papillomavirus (HPV) Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country (2019-2024)
Table 37. Americas Human Papillomavirus (HPV) Vaccines Sales by Type (2019-2024) & (K Units)
Table 38. Americas Human Papillomavirus (HPV) Vaccines Sales by Application (2019-2024) & (K Units)
Table 39. APAC Human Papillomavirus (HPV) Vaccines Sales by Region (2019-2024) & (K Units)
Table 40. APAC Human Papillomavirus (HPV) Vaccines Sales Market Share by Region (2019-2024)
Table 41. APAC Human Papillomavirus (HPV) Vaccines Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Human Papillomavirus (HPV) Vaccines Revenue Market Share by Region (2019-2024)
Table 43. APAC Human Papillomavirus (HPV) Vaccines Sales by Type (2019-2024) & (K Units)
Table 44. APAC Human Papillomavirus (HPV) Vaccines Sales by Application (2019-2024) & (K Units)
Table 45. Europe Human Papillomavirus (HPV) Vaccines Sales by Country (2019-2024) & (K Units)
Table 46. Europe Human Papillomavirus (HPV) Vaccines Sales Market Share by Country (2019-2024)
Table 47. Europe Human Papillomavirus (HPV) Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country (2019-2024)
Table 49. Europe Human Papillomavirus (HPV) Vaccines Sales by Type (2019-2024) & (K Units)
Table 50. Europe Human Papillomavirus (HPV) Vaccines Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Human Papillomavirus (HPV) Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Human Papillomavirus (HPV) Vaccines
Table 58. Key Market Challenges & Risks of Human Papillomavirus (HPV) Vaccines
Table 59. Key Industry Trends of Human Papillomavirus (HPV) Vaccines
Table 60. Human Papillomavirus (HPV) Vaccines Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Human Papillomavirus (HPV) Vaccines Distributors List
Table 63. Human Papillomavirus (HPV) Vaccines Customer List
Table 64. Global Human Papillomavirus (HPV) Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Human Papillomavirus (HPV) Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Human Papillomavirus (HPV) Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Human Papillomavirus (HPV) Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Human Papillomavirus (HPV) Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Human Papillomavirus (HPV) Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Human Papillomavirus (HPV) Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Human Papillomavirus (HPV) Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Human Papillomavirus (HPV) Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Human Papillomavirus (HPV) Vaccines Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Human Papillomavirus (HPV) Vaccines Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Human Papillomavirus (HPV) Vaccines Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Human Papillomavirus (HPV) Vaccines Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Merck Basic Information, Human Papillomavirus (HPV) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Human Papillomavirus (HPV) Vaccines Product Portfolios and Specifications
Table 80. Merck Human Papillomavirus (HPV) Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. GSK Basic Information, Human Papillomavirus (HPV) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Human Papillomavirus (HPV) Vaccines Product Portfolios and Specifications
Table 85. GSK Human Papillomavirus (HPV) Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Walvax Basic Information, Human Papillomavirus (HPV) Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Walvax Human Papillomavirus (HPV) Vaccines Product Portfolios and Specifications
Table 90. Walvax Human Papillomavirus (HPV) Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Walvax Main Business
Table 92. Walvax Latest Developments
List of


Figure 1. Picture of Human Papillomavirus (HPV) Vaccines
Figure 2. Human Papillomavirus (HPV) Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Papillomavirus (HPV) Vaccines Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Human Papillomavirus (HPV) Vaccines Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Human Papillomavirus (HPV) Vaccines Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of 2-Valent Vaccine
Figure 10. Product Picture of 4-Valent Vaccine
Figure 11. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Type in 2023
Figure 12. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Type (2019-2024)
Figure 13. Human Papillomavirus (HPV) Vaccines Consumed in Research & Academic Laboratories
Figure 14. Global Human Papillomavirus (HPV) Vaccines Market: Research & Academic Laboratories (2019-2024) & (K Units)
Figure 15. Human Papillomavirus (HPV) Vaccines Consumed in Pharmaceutical & Biotechnology Companies
Figure 16. Global Human Papillomavirus (HPV) Vaccines Market: Pharmaceutical & Biotechnology Companies (2019-2024) & (K Units)
Figure 17. Human Papillomavirus (HPV) Vaccines Consumed in Others
Figure 18. Global Human Papillomavirus (HPV) Vaccines Market: Others (2019-2024) & (K Units)
Figure 19. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Application (2023)
Figure 20. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Application in 2023
Figure 21. Human Papillomavirus (HPV) Vaccines Sales Market by Company in 2023 (K Units)
Figure 22. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Company in 2023
Figure 23. Human Papillomavirus (HPV) Vaccines Revenue Market by Company in 2023 ($ Million)
Figure 24. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Company in 2023
Figure 25. Global Human Papillomavirus (HPV) Vaccines Sales Market Share by Geographic Region (2019-2024)
Figure 26. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share by Geographic Region in 2023
Figure 27. Americas Human Papillomavirus (HPV) Vaccines Sales 2019-2024 (K Units)
Figure 28. Americas Human Papillomavirus (HPV) Vaccines Revenue 2019-2024 ($ Millions)
Figure 29. APAC Human Papillomavirus (HPV) Vaccines Sales 2019-2024 (K Units)
Figure 30. APAC Human Papillomavirus (HPV) Vaccines Revenue 2019-2024 ($ Millions)
Figure 31. Europe Human Papillomavirus (HPV) Vaccines Sales 2019-2024 (K Units)
Figure 32. Europe Human Papillomavirus (HPV) Vaccines Revenue 2019-2024 ($ Millions)
Figure 33. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales 2019-2024 (K Units)
Figure 34. Middle East & Africa Human Papillomavirus (HPV) Vaccines Revenue 2019-2024 ($ Millions)
Figure 35. Americas Human Papillomavirus (HPV) Vaccines Sales Market Share by Country in 2023
Figure 36. Americas Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country in 2023
Figure 37. Americas Human Papillomavirus (HPV) Vaccines Sales Market Share by Type (2019-2024)
Figure 38. Americas Human Papillomavirus (HPV) Vaccines Sales Market Share by Application (2019-2024)
Figure 39. United States Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 40. Canada Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 41. Mexico Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 42. Brazil Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 43. APAC Human Papillomavirus (HPV) Vaccines Sales Market Share by Region in 2023
Figure 44. APAC Human Papillomavirus (HPV) Vaccines Revenue Market Share by Regions in 2023
Figure 45. APAC Human Papillomavirus (HPV) Vaccines Sales Market Share by Type (2019-2024)
Figure 46. APAC Human Papillomavirus (HPV) Vaccines Sales Market Share by Application (2019-2024)
Figure 47. China Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 48. Japan Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 49. South Korea Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 50. Southeast Asia Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 51. India Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 52. Australia Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 53. China Taiwan Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 54. Europe Human Papillomavirus (HPV) Vaccines Sales Market Share by Country in 2023
Figure 55. Europe Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country in 2023
Figure 56. Europe Human Papillomavirus (HPV) Vaccines Sales Market Share by Type (2019-2024)
Figure 57. Europe Human Papillomavirus (HPV) Vaccines Sales Market Share by Application (2019-2024)
Figure 58. Germany Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 59. France Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 60. UK Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 61. Italy Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 62. Russia Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 63. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales Market Share by Country in 2023
Figure 64. Middle East & Africa Human Papillomavirus (HPV) Vaccines Revenue Market Share by Country in 2023
Figure 65. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales Market Share by Type (2019-2024)
Figure 66. Middle East & Africa Human Papillomavirus (HPV) Vaccines Sales Market Share by Application (2019-2024)
Figure 67. Egypt Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 68. South Africa Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 69. Israel Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 70. Turkey Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 71. GCC Country Human Papillomavirus (HPV) Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Human Papillomavirus (HPV) Vaccines in 2023
Figure 73. Manufacturing Process Analysis of Human Papillomavirus (HPV) Vaccines
Figure 74. Industry Chain Structure of Human Papillomavirus (HPV) Vaccines
Figure 75. Channels of Distribution
Figure 76. Global Human Papillomavirus (HPV) Vaccines Sales Market Forecast by Region (2025-2030)
Figure 77. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share Forecast by Region (2025-2030)
Figure 78. Global Human Papillomavirus (HPV) Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 79. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share Forecast by Type (2025-2030)
Figure 80. Global Human Papillomavirus (HPV) Vaccines Sales Market Share Forecast by Application (2025-2030)
Figure 81. Global Human Papillomavirus (HPV) Vaccines Revenue Market Share Forecast by Application (2025-2030)

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (09 May, 2026)
  • Notify To Team (09 May, 2026)
  • Report updation (10 May, 2026)
  • Report Quality Check (10 May, 2026)
  • Report Dispatch (11 May, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Human Papillomavirus (HPV) Vaccines Market Growth 2024-2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.